Carolina M. Reyes, Ph.D.
Affiliations: | 2000 | University of California, San Francisco, San Francisco, CA |
Area:
computational chemistry, molecular modeling and bioinformaticsGoogle:
"Carolina Reyes"Mean distance: 9 | S | N | B | C | P |
Parents
Sign in to add mentor| Peter A. Kollman | grad student | 2000 | UCSF | |
| (Structure and thermodynamics of RNA -protein interactions.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Reyes C, Engel-Nitz NM, DaCosta Byfield S, et al. (2019) Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma. The Oncologist |
| Reyes C, Engel-Nitz NM, DaCosta Byfield S, et al. (2019) Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer. The Oncologist |
| Satram-Hoang S, Bajaj P, Stein A, et al. (2019) Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data Journal of Cancer Therapy. 10: 117-133 |
| Satram-Hoang S, Stein A, Cortazar P, et al. (2019) Increased Mortality Risk among Early Stage Hormone Receptor Positive Breast Cancer Patients Who Did Not Receive Adjuvant or Neoadjuvant Therapy Journal of Cancer Therapy. 10: 1-20 |
| Guzauskas GF, Masaquel A, Reyes C, et al. (2018) Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. Journal of Medical Economics. 1-18 |
| Reyes C, Gauthier G, Shi S, et al. (2018) Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia Journal of Cancer Therapy. 9: 576-587 |
| Burudpakdee C, Seetasith A, Reyes CM, et al. (2018) What are the drivers of healthcare cost among patients with metastatic breast cancer (mBC)? Total cost of care analysis to inform value-based reimbursement. Journal of Clinical Oncology. 36: 1092-1092 |
| Mansfield C, Masaquel A, Sutphin J, et al. (2017) Patients' priorities in selecting chronic lymphocytic leukemia treatments. Blood Advances. 1: 2176-2185 |
| Stokes M, Reyes C, Xia Y, et al. (2017) Impact of pharmacy channel on adherence to oral oncolytics. Bmc Health Services Research. 17: 414 |
| Matasar MJ, Byfield SD, Blauer-Peterson C, et al. (2017) What are the health care costs for chronic lymphocytic leukemia Journal of Clinical Oncology. 35: 15-15 |